McGuire Investment Group LLC Has $94,000 Holdings in Recursion Pharmaceuticals, Inc. $RXRX

McGuire Investment Group LLC cut its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 21.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,500 shares of the company’s stock after selling 5,000 shares during the quarter. McGuire Investment Group LLC’s holdings in Recursion Pharmaceuticals were worth $94,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Janney Montgomery Scott LLC acquired a new stake in Recursion Pharmaceuticals in the 2nd quarter worth $51,000. Kieckhefer Group LLC acquired a new stake in Recursion Pharmaceuticals in the 2nd quarter worth $192,000. Farther Finance Advisors LLC grew its position in Recursion Pharmaceuticals by 83.7% in the 2nd quarter. Farther Finance Advisors LLC now owns 14,202 shares of the company’s stock worth $72,000 after purchasing an additional 6,470 shares during the last quarter. Rhumbline Advisers grew its position in Recursion Pharmaceuticals by 7.5% in the 1st quarter. Rhumbline Advisers now owns 359,175 shares of the company’s stock worth $1,900,000 after purchasing an additional 25,143 shares during the last quarter. Finally, Focus Partners Wealth acquired a new stake in Recursion Pharmaceuticals in the 1st quarter worth $77,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Recursion Pharmaceuticals

In related news, insider Najat Khan sold 36,599 shares of Recursion Pharmaceuticals stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.52, for a total transaction of $202,026.48. Following the completion of the transaction, the insider directly owned 668,197 shares of the company’s stock, valued at $3,688,447.44. This trade represents a 5.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.43% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Morgan Stanley assumed coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price target on the stock. Needham & Company LLC restated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $7.25.

Recursion Pharmaceuticals Trading Up 4.5%

Shares of RXRX stock opened at $5.10 on Thursday. Recursion Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $12.36. The company has a market capitalization of $2.21 billion, a P/E ratio of -2.87 and a beta of 0.91. The firm has a 50-day moving average price of $5.14 and a 200 day moving average price of $5.16. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The firm had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. During the same period in the prior year, the business earned ($0.40) earnings per share. The company’s revenue for the quarter was up 33.3% on a year-over-year basis. Research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.